Welcome to the SEER Inquiry System (SINQ). SINQ is a collection of questions that
cancer registrars have had while coding cancer cases. Click Search to look for
specific questions or to select questions for a Report.
MP/H Rules/Histology--Esophagus: Biopsy of esophagus - path report states "adenocarcinoma, intestinal type". There is no evidence of a gastric tumor in scans or EDG. There is a rule for colon to disregard "intestinal type" and code to adenocarcinoma (8140) but no rule for esophagus. How should histology for this esophageal case be coded?
Reportability/Ambiguous Terminology--Prostate:
Text from prostate biopsy states "highly suspicious for but not diagnostic of adenocarcinoma suggest another biopsy" Is this case reportable?
MP/H Rules/Histology--Thyroid: What is the correct histology for these thyroid tumors? In each case, the path report reads, "Papillary sclerosing carcinoma." In one case, the results are in CAP protocol format and next to 'Encapsulation of tumor' it says 'No.' In the other case, it is not in CAP format, but the microscopic description says, 'encapsulation of tumor - no.' Is the correct code 8350?
MP/H Rules/Histology--Melanoma: Path: Melanoma in situ, lentiginous type, skin rt lower leg. Is this the same as acral lentiginous melanoma (8744)? To code to 8744, do we specifically have to see the word "acral" lentiginous melanoma? Please see discussion.
MP/H Rules/Histology: Final diagnosis from a partial vulvectomy says, "vulvar intraepithelial neoplasia III, basaloid type." Is this VIN III (8077/2) or basaloid squamous cell carcinoma (8083 and change the bevavior code from 3 to 2)? Which Histology rule applies? It seems to me that H4 and H6 both lead to 8083.
Histology--Lymphoma: If two different histologies of the same type of Lymphoma (two different histologies for NHL: DLBCL 9680/3 + Mantle Cell Lymphoma 9673/3) occur in the same time in different lymph nodes, how do we code the histology, and what would be the sequence number if this would be considered as multiple primaries? Please see discussion.
MP/H Rules/Multiple primaries--Breast: When an in situ diagnosis is followed by an invasive diagnosis in the same breast 1.5 years later, is it a new primary? See discussion.
CS Site Specific Factor--Prostate: Please clarify how SEER registries should use code 40 for site-specific factor 3 on prostate cases. Please see discussion.
Reportability: Are squamous cell carcinomas arising in a condyloma of the rectum reportable or should we assume that the site is skin of anus or perianal and not reportable?
Race--How and when is Appendix D – Race and Nationality Descriptions from the 2000 Census and Bureau of Vital Statistics to be used? Please see discussion.
